Alpha Modus Holdings Inc (AMOD): $AMOD always thinking ahead. https://al...

Trooperstocks · 2025-03-10T18:58:11.8070000Z

$AMOD always thinking ahead. https://alphamodus.com https://x.com/AlphaModus/status/1899162915975946422

Play Episode

11min

Proactive - Interviews for investors

Ecora Resources sees strong 2024 results as cobalt, copper growth drive strategy

Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) CEO Marc Bishop Lafleche takes Proactive's Stephen Gunnion through the company’s full-year 2024 financial results and the strategic progress made across its royalty portfolio. Lafleche reported a strong performance in 2024 despite challenging market conditions, citing volume growth at Voisey’s Bay as a key highlight, even as cobalt prices approached 50-year lows. He said, “Since year-end, actually, it's amazing how quickly things can change,” pointing to a 60–70% year-to-date increase in cobalt prices. Ecora’s focus remained on expanding its base metals exposure, with 80% of its portfolio now weighted toward critical minerals, particularly copper. The company emphasised that royalties offer long-term exposure, with copper making up 50% of its estimated net asset value. Lafleche also detailed major portfolio drivers for 2025, including expected volume growth from Voisey’s Bay, Mantos Blancos, and the newly acquired Mimbula Copper Stream. Looking further ahead, he highlighted potential upside from de-bottlenecking and tailings processing projects at Mantos Blancos and progress at Santo Domingo, Phalaborwa, and Piauí. For more updates on Ecora Resources and other companies in the critical minerals space, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #EcoraResources #CriticalMinerals #RoyaltyInvesting #Copper #Cobalt #VoiseysBay #MantosBlancos #MiningNews #BaseMetals #ProactiveInvestors #Commodities #ElectricFuture #SustainableMining

Proactive - Interviews for investors

SomnoMed lifts revenue 19% amid soaring demand

SomnoMed CO-CEOs Amrita Blickstead and Karen Borg talked with Proactive about the company’s performance and opportunities in the global sleep apnea treatment market. The company, which develops proprietary oral appliances for obstructive sleep apnea, is seeing significant demand as patients seek alternatives to traditional CPAP therapy. “About 60% of people fail to be able to use actual CPAP therapy because it’s quite invasive,” Borg explained. SomnoMed’s devices offer a less intrusive solution and are distributed through dental channels in 28 countries, with strong uptake in the United States and Western Europe. The co-CEOs discussed a major tailwind from the rising use of GLP-1 therapies for weight loss, which is pushing more patients to explore alternative sleep apnea treatments. Increased public awareness of sleep wellness through apps and consumer health trends is also fueling demand. To meet this growth, Blickstead said their immediate focus was on ensuring “the right foundation for profitable growth.” This included strengthening the company’s financial base, reducing costs, paying down debt, and investing heavily in manufacturing. Production capacity has increased by over 40%, with revenue up 19% year-on-year and EBITDA for the first half reaching AUD 5.80 million, compared to a AUD 1.10 million loss previously. Despite these gains, Blickstead noted they are still “chasing our tails and trying to make enough product to continue to grow this business.” #SomnoMed #SleepApnea #OralAppliance #HealthcareInnovation #CPAPAlternative #GLP1 #SleepTech #MedicalDevices #HealthInvesting #ProactiveInvestors

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Technology Minerals CEO on black mass and Leinster milestones

Technology Minerals CEO Alex Stanbury talked with Proactive's Stephen Gunnion about a milestone week for the company, highlighting significant progress in both its recycling operations and exploration asset portfolio. Stanbury discussed the first shipment of black mass from its Recyclus facility to Europe, under an agreement with Glencore. He explained that black mass—a hazardous material containing lithium, cobalt, and nickel—requires complex approvals for cross-border movement. “It’s been a lot of work in the making to get this black mass moved off-site,” Stanbury said, noting this completes a critical part of the company’s business model. He also commented on the importance of the Glencore partnership, stating that “for Glencore to have the faith to work with us…is really important.” This collaboration ensures a consistent offtake of all Recyclus production. Stanbury also confirmed Recyclus is working with Ocado, managing end-of-life batteries from their robotic systems. The company uses its proprietary LiBoxes to safely store and transport used lithium-ion batteries, providing safety and ESG compliance. “We’ve done thousands of batteries for them now and there’s an ongoing maintenance programme,” he added. Finally, Technology Minerals has completed the sale of its Leinster lithium project in Ireland, aligning with its strategy of incubating early-stage assets and moving them up the value curve. The company is now focused on its Spanish project, which benefits from EU interest in critical materials and battery manufacturing. It expects further licenses to be granted soon and aims to seek JV partners to bring the project toward feasibility and production. For more updates, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #TechnologyMinerals #Recyclus #Glencore #BlackMass #BatteryRecycling #CriticalMetals #Ocado #LithiumRecycling #LiBoxes #ESG #SustainableMining #E

Followers	1336
Posts	257912
Boards Moderated	60
Alias Born	12/07/2009

Volume:	3
Day Range:
Bid:	1.26
Ask:	1.32
Last Trade Time:	4:23:27 AM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AMOD Detailed Quote

Recent AMOD News

More AMOD News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent AMOD News

Go Ad-Free